Literature DB >> 19808354

Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.

Ravi V Shah1, Annabel A Chen-Tournoux, Michael H Picard, Roland R J van Kimmenade, James L Januzzi.   

Abstract

BACKGROUND: ST2, a biomarker of cardiomyocyte stretch, powerfully predicts poor outcomes in patients with acute dyspnea, but nothing is known about associations between soluble ST2 (sST2) and cardiac structure and function, or whether sST2 retains prognostic meaning in the context of such measures. METHODS AND
RESULTS: One hundred thirty-four dyspneic patients with and without decompensated heart failure had echocardiography during index admission and vital status was ascertained at 4 years. Echocardiographic and clinical correlates of sST2 as well as independent predictors of death at 4 years were identified. sST2 correlated with left ventricular end-systolic dimensions/volumes and left ventricular ejection fraction. sST2 was inversely associated with right ventricular fractional area change (rho=-0.18; P=0.046), higher right ventricular systolic pressure (rho=0.26; P=0.005), and right ventricular hypokinesis (P<0.001) and was correlated with tissue Doppler Ea wave peak velocity, but not to other indices of diastolic function. In multivariate regression, independent predictors of sST2 included right ventricular systolic pressure (t=2.29; P=0.002), left ventricular ejection fraction (t=-2.15; P=0.05) and dimensions (end systolic, t=2.57; end diastolic, t=2.98; both P<0.05), amino-terminal pro-B-type natriuretic peptide (t=3.31; P=0.009), heart rate (t=2.59; P=0.01), and presence of jugular venous distension (t=2.00; P=0.05). In a Cox proportional hazards model that included echocardiographic results and other biomarkers, sST2 independently predicted death at 4 years (hazard ratio=2.70; P=0.003).
CONCLUSIONS: Among dyspneic patients with and without acute heart failure, sST2 concentrations are associated with prevalent cardiac abnormalities on echocardiography, a more decompensated hemodynamic profile and are associated with long-term mortality, independent of echocardiographic, clinical, or other biochemical markers of risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808354     DOI: 10.1161/CIRCHEARTFAILURE.108.833707

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  53 in total

Review 1.  ST2: a novel remodeling biomarker in acute and chronic heart failure.

Authors:  Ravi V Shah; James L Januzzi
Journal:  Curr Heart Fail Rep       Date:  2010-03

2.  Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.

Authors:  Jennifer E Ho; Wei-Yu Chen; Ming-Huei Chen; Martin G Larson; Elizabeth L McCabe; Susan Cheng; Anahita Ghorbani; Erin Coglianese; Valur Emilsson; Andrew D Johnson; Stefan Walter; Nora Franceschini; Christopher J O'Donnell; Abbas Dehghan; Chen Lu; Daniel Levy; Christopher Newton-Cheh; Honghuang Lin; Janine F Felix; Eric R Schreiter; Ramachandran S Vasan; James L Januzzi; Richard T Lee; Thomas J Wang
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.

Authors:  Catherine E Simpson; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie K Nies; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Eric D Austin; D Dunbar Ivy; William C Nichols; Allen D Everett
Journal:  Chest       Date:  2020-01-25       Impact factor: 9.410

Review 4.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

5.  The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects.

Authors:  D B Ojji; L H Opie; S Lecour; L Lacerda; O M Adeyemi; K Sliwa
Journal:  J Hum Hypertens       Date:  2014-01-09       Impact factor: 3.012

Review 6.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 7.  ST2 as a cardiovascular risk biomarker: from the bench to the bedside.

Authors:  James L Januzzi
Journal:  J Cardiovasc Transl Res       Date:  2013-04-05       Impact factor: 4.132

8.  Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.

Authors:  Devin M Parker; Allen D Everett; Meagan E Stabler; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Heather Thiessen-Philbrook; Chirag R Parikh; Jeremiah R Brown
Journal:  J Card Surg       Date:  2019-04-03       Impact factor: 1.620

Review 9.  Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Trends Cardiovasc Med       Date:  2016-07-28       Impact factor: 6.677

10.  Soluble ST2 predicts elevated SBP in the community.

Authors:  Jennifer E Ho; Martin G Larson; Anahita Ghorbani; Susan Cheng; Ramachandran S Vasan; Thomas J Wang; James L Januzzi
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.